Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
Laura BudauChristian WilhelmRoland MollJörg JäkelCarsten HirtGottfried DölkenGeorg MaschmeyerEllen NeubauerKonstantin StrauchAndreas BurchertMichael HeroldAndreas NeubauerPublished in: Journal of cancer research and clinical oncology (2019)
Rituximab may overcome immune-dormancy in follicular lymphoma in cases with lower intrafollicular T-cell numbers and higher CD56 and CD68 cell counts. As this was a retrospective analysis on a small subgroup of patients, these data need to be corroborated in larger clinical trials.
Keyphrases
- clinical trial
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- single cell
- hodgkin lymphoma
- electronic health record
- stem cells
- squamous cell carcinoma
- chronic lymphocytic leukemia
- big data
- mesenchymal stem cells
- open label
- phase iii
- deep learning
- rectal cancer
- data analysis
- patient reported